Antifebrile Effects Of Dexibuprofen Suppository On Children With High Fever

Read full text Summarise with VIRAT
Authors: Zhiyang Wu
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Acute fever is a frequently-seen disease in the department of paediatrics. OBJECTIVE: This study aims to evaluate the antipyretic efficacy of dexibuprofen suppositories in pediatric patients with high fever. METHODS: 100 children with high fever who received antipyretic treatment in our hospital from March 2022 to March 2023 were retrospectively analysed. Among them, 57 children treated with dexibuprofen suppositories were taken as the study group and 43 children treated with ibuprofen suspension were taken as the control group. The body temperatures of the two groups were analyzed and compared before medication and at 0.5, 1, 2, 4 and 6 hrs after medication. The two groups were compared in the therapeutic effects and adverse reactions. Independent sample t-tests and repeated measures analysis of variance were used for comparisons between groups and chi-square tests or Fisher's exact tests were used for categorical variables. RESULTS: The study group had significantly lower temperatures at 0.5, 2, 4 and 6 hrs (P < 0.0001), with similar overall efficacy (P > 0.05) and fewer adverse reactions (P = 0.0272). Multivariate logistic regression analysis determined that the disease course and admission body temperature were independent risk factors. CONCLUSION: Dexibuprofen suppository provides rapid and effective antipyresis with better safety in pediatric emergency settings.

Fields of Study & Subjects

Thermal Regulation in Medicine Pharmaceutical studies and practices General Medicine and Therapeutics

Publication details

Journal / source
Pakistan Journal of Pharmaceutical Sciences
Volume
39
Issue
5
Pages
1254–1261
Publication date
23 February 2026
Language
EN